Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF‐1, and IGFBP‐3 and prostate cancer risk in African‐American men: The Flint Men's Health Study
The Prostate2007Vol. 68(3), pp. 296–305
Citations Over TimeTop 10% of 2007 papers
Aruna V. Sarma, Rodney L. Dunn, Leslie A. Lange, Anna M. Ray, Yunfei Wang, Ethan M. Lange, Kathleen A. Cooney
Abstract
These findings suggest that variation in or around CYP17 and/or IGF1 may be associated with prostate cancer development in the African-American population. Additional studies are needed to determine whether these polymorphisms are indeed associated with prostate cancer risk in African Americans.
Related Papers
- → Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by Ketoconazole(2004)33 cited
- → Mechanism-based Inhibition Profiles of Erythromycin and Clarithromycin with Cytochrome P450 3A4 Genetic Variants(2013)33 cited
- [Cytochrome P-450 3A4--the most important arena for drug interactions in the body].(2008)
- Drug Interaction Related to CYP3A4(2001)
- Influence of 4 anti-tumor traditional Chinese medicine injections on activities of cytochrome P4503A4 in rat liver microsomes(2014)